Form IRANNOTICE Solventum Corp
Tweet
Share
E-mail
2510 Conway Ave E.
Building 275-6W-20
St. Paul, MN 55144
February 28, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Re: Notice of disclosure filed in Exchange Act Quarterly Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Ladies and Gentlemen:
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Solventum Corporation has made disclosure pursuant to those provisions in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the Securities and Exchange Commission on February 28, 2025.
| Respectfully submitted, | |||||||||||||||||
| /s/ Matthew M. Rice | |||||||||||||||||
| Matthew M. Rice | |||||||||||||||||
| Vice President, Associate General Counsel & Assistant Secretary | |||||||||||||||||
| Solventum Corporation | |||||||||||||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paris Baguette Expands Their Growing Footprint with a New Café Opening in Williamsville on August 31
- Floki Price Prediction Stalls 92% Below Its Peak While Early Wallets Race Into Pepeto
- Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
